Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inhibrx Biosciences Inc (NQ: INBX ) 14.56 +0.65 (+4.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 146,381 Open 14.06 Bid (Size) 14.50 (1) Ask (Size) 14.67 (1) Prev. Close 13.91 Today's Range 13.95 - 14.67 52wk Range 10.80 - 39.79 Shares Outstanding 37,892,204 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying August 27, 2024 Via Benzinga INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024 August 22, 2024 INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Performance YTD -61.72% -61.72% 1 Month -0.07% -0.07% 3 Month -19.20% -19.20% 6 Month -59.15% -59.15% 1 Year -35.43% -35.43% More News Read More INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024 August 14, 2024 Via InvestorPlace Top 4 Health Care Stocks That Are Preparing To Pump This Month June 05, 2024 Via Benzinga INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX May 09, 2024 From Kahn Swick & Foti, LLC Via Business Wire JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know August 23, 2023 Via Benzinga Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients April 26, 2023 Via Benzinga Why Is Inhibrx (INBX) Stock Soaring 45% Today? October 04, 2022 Via InvestorPlace The NVDA Earnings Effect And What It Means For The Current Market Momentum February 28, 2024 Via Talk Markets Topics Stocks Exposures US Equities Is The Stock Market Ready To Plunge? The Warning Signs Are Here... February 21, 2024 Via Talk Markets INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX February 10, 2024 From Kahn Swick & Foti, LLC Via Business Wire Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx January 23, 2024 Via Investor's Business Daily INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders January 23, 2024 From Halper Sadeh LLC Via Business Wire French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B January 23, 2024 Via Benzinga Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project January 23, 2024 Via Benzinga $1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying August 31, 2023 Via Benzinga Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session August 29, 2023 Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday August 29, 2023 Via Benzinga Topics Stocks Exposures US Equities Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating May 03, 2023 Via Investor's Business Daily Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate November 16, 2022 Via Benzinga $40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying October 13, 2022 Via Benzinga Stocks Reverse Gains After ADP Report October 05, 2022 Via Talk Markets Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday November 18, 2022 Via Benzinga S&P 500 Rises 100 Points; Nasdaq Up 3% October 04, 2022 Via Benzinga R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing October 05, 2022 Via FinancialNewsMedia Topics Death Exposures Death Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
